Cumberland Pharmaceuticals Inc
CPIXHealthcare·Drug Manufacturers - Specialty & Generic·USA·Micro·NASD·Nov 12 • 3:59 PM ET
6.63+0.51 (8.33%)
2026-11-13 13:26 CET
Market cap
$99.34M
Revenue, TTM
25.13 USD m
Net income, TTM
-11.83 USD m
Free cash flow, TTM
-0.99 USD m
EPS diluted, TTM
-0.79
Price
CPIX against its 20, 50 and 200-day averagesPatternshover a marker to name it
28.6% under the 52-week high of 9.28 on 26 Aug 2026. 52-week low 1.44 on 18 Nov 2025. Last 15 sessions, 114.7% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 72
CANSLIM 1 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); 52-Week High/Low: 0-10% below High; Institutional Ownership: Over 50%; Average Volume: Over 200K — not on the tape: EPS Growth This Year: High (>25%)
VCP 5 of 6 — fails: 52-Week High/Low: 0-10% below High
Minervini 3 of 4 — fails: 52-Week High/Low: 0-10% below High
Zanger 3 of 5 — fails: 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5
Leaders 2 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 1 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); Return on Equity: Over +15% — not on the tape: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%)
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 3 of 4 — fails: Average Volume: Over 500K
Accumulation 2 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%
Relative Strength 2 of 3 — fails: Average Volume: Over 500K
Profile
CPIX52-week range, 66% of the way up
1.449.28
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. It operates through the following geographical segments: China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The firm products include Acetadote, Caldolor, Kristalose, Vaprisol, Talicia, Vibativ, Sancuso, Omeclamox, RediTrex, and Other. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.
| Employees | 93 |
|---|---|
| IPO | Aug 11, 2009 |
| Beta | 0.27 |
| ATR, 14d | 0.80 |
| Rel volume | 0.00 |
| Short float | 3.43% |
| Insider own | 41.60% |
| Inst own | 21.26% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $99.34M |
| Enterprise Value | 23.03M |
| Income | -11.83M |
| Sales | 25.13M |
| Book / share | 4.84 |
| Cash / share | 5.38 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | Aug 03, 2026 |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 93 |
| IPO | Aug 11, 2009 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 3.95 |
| Price / book | 1.37 |
| Price / cash | 1.23 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 0.92 |
| Quick Ratio | 3.04 |
| Current Ratio | 3.05 |
| Debt / equity | 0.06 |
| Long-term debt / equity | 0.06 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -0.79 |
|---|---|
| Earnings next year | - |
| Earnings next quarter | - |
| Earnings this year | - |
| Earnings next year | - |
| Earnings growth, 5 years | - |
| Past earnings growth | 20.68% 2.82% |
| Past sales growth | 1.95% 3.52% |
| Earnings vs last year | -241.27% |
| Sales vs last year | -39.11% |
| Earnings vs last quarter | -46.49% |
| Sales vs last quarter | -74.00% |
| Earnings | Nov 10 AMC |
| Surprise | - - |
Ownership
| Insiders own | 41.60% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 21.26% |
| Institution trades | -6.64% |
| Return on assets | -9.94% |
| Return on equity | -18.11% |
| Return on capital | -15.44% |
| Gross Margin | 81.43% |
| Operating margin | -36.72% |
| Profit Margin | -47.05% |
| 20-day average | 13.52% |
| 50-day average | -0.37% |
| 200-day average | 35.65% |
Technical
| Shares out | 14.99M |
|---|---|
| Shares floating | 8.75M |
| Short / float | 3.43% |
| Short ratio | 2.78 |
| Short interest | 0.30M |
| 52-week high | 9.28 -28.6% |
| 52-week low | 1.44 +362.0% |
| Volatility | 17.57% 16.64% |
| Average range | 0.80 |
| Strength index | 55.75 |
| Market sensitivity | 0.27 |
| Relative volume | 0.00 |
| Avg Volume | 107.85K |
| Volume | 0 |
Performance
| Perf Week | 32.34% |
|---|---|
| Perf Month | -11.48% |
| Perf Quarter | -14.89% |
| Perf Half Y | 73.78% |
| Perf YTD | 114.82% |
| Perf Year | 299.53% |
| Perf 3Y | 383.04% |
| Perf 5Y | 217.84% |
| Perf 10Y | 71.68% |
| Recommendation | 1.00 |
| Target Price | 9.75 |
| Prev Close | 6.63 |
| Price | 6.63 |
| Change % | 0.00% |
Analyst ratings
latest 7 of 7| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Nov 12, 2012 | Reiterated | UBS | Neutral | $6.50 → $5 | -24.6% |
| Feb 01, 2011 | Reiterated | UBS | Neutral | $8 → $6.50 | -2.0% |
| Dec 16, 2010 | Downgrade | UBS | Buy → Neutral | $10 → $8 | +20.7% |
| Aug 17, 2010 | Reiterated | UBS | Buy | $11 → $10 | +50.8% |
| Aug 17, 2010 | Reiterated | Morgan Joseph | Buy | $15 → $10 | +50.8% |
| Aug 17, 2010 | Downgrade | Jefferies | Buy → Hold | $13 → $5.50 | -17.0% |
| May 14, 2010 | Reiterated | Morgan Joseph | Buy | $21 → $15 | +126.2% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| TLPH | Talphera Inc | 53.46M |
| PCRX | Pacira BioSciences Inc | 1.46B |
| HRTX | Heron Therapeutics Inc | 66.60M |
| COLL | Collegium Pharmaceutical Inc | 775.33M |
| DERM | Journey Medical Corp | 123.91M |
| ETON | Eton Pharmaceuticals Inc | 1.77B |
| ANIP | ANI Pharmaceuticals Inc | 1.62B |
| AQST | Aquestive Therapeutics Inc | 448.71M |
| CRMD | CorMedix Inc | 396.74M |
| CAPR | Capricor Therapeutics Inc | 596.54M |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.64B |
| DFMC | U.S. Micro Cap Portfolio ETF Class Shares | AUM: 213.58M |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| BUSM | EA Bridgeway Ultra-Small Company Market ETF | AUM: 112.81M |
| DFAT | U.S. Targeted Value Portfolio-ETF Class Shares | AUM: 14.54B |
| DFAC | U.S. Core Equity 2 Portfolio-ETF Class Shares | AUM: 49.67B |
| AVSC | Avantis U.S Small Cap Equity ETF | AUM: 3.33B |
| DFSU | Dimensional US Sustainability Core 1 ETF | AUM: 2.40B |
News
latest 14 of 200- Cumberland's $77.8 Million Gain Is Accounting; The Real Story Is An Ifetroban NDA That Rests On Natural-History Data (Earnings Whispers) +15.47%
- Cumberland: Q3 Earnings Snapshot (Associated Press)
- CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire)
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS (PR Newswire)
- CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM (PR Newswire) -48.76% +13.79%
- Cumberland Pharmaceuticals stock tumbles on trial results (Investing.com)
- Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results (PR Newswire)
- CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL (PR Newswire)
- CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM (PR Newswire) -6.69% +18.81%
- Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ... (GuruFocus.com)
- Cumberland: Q2 Earnings Snapshot (Associated Press) +8.22%
- CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS (PR Newswire)
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS (PR Newswire)
- CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE (PR Newswire) +10.29%
Quarterly earnings
2026Q1 EPS -0.130, from 0.160 a year earlier. Sales 9.13, from 11.71 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q1ended 2026-03-31 | 2026-05-05 16:30 | -0.130 | - | -0.220 | 9.13 | - | EPS - · sales - | vs 2025Q1, year-ago quarter · EPS -181.3% · sales -22.0% | - | Open -0.88% vs SPY +0.61%. Close -3.96% vs SPY +1.39% |
| 2025Q4ended 2025-12-31 | 2026-03-03 16:30 | - | - | -0.094 | 13.68 | - | EPS - · sales - | vs 2024Q4, year-ago quarter · EPS - · sales +31.1% | - | Open 0.00% vs SPY +0.19%. Close -19.87% vs SPY +0.71% |
| 2025Q3ended 2025-09-30 | 2025-11-04 16:30 | 0.060 | - | -0.130 | 8.29 | - | EPS - · sales - | vs 2024Q3, year-ago quarter · EPS - · sales -8.7% | - | Open -2.63% vs SPY -0.04%. Close -12.41% vs SPY +0.35% |
| 2025Q2ended 2025-06-30 | 2025-08-05 16:30 | 0.020 | - | -0.050 | 10.84 | - | EPS - · sales - | vs 2024Q2, year-ago quarter · EPS +100.0% · sales +10.0% | - | Open -22.16% vs SPY +0.17%. Close -15.30% vs SPY +0.77% |
| 2025Q1ended 2025-03-31 | 2025-05-06 16:30 | 0.160 | - | 0.082 | 11.71 | - | EPS - · sales - | vs 2024Q1, year-ago quarter · EPS -420.0% · sales +37.8% | - | Open +7.37% vs SPY +0.24%. Close +0.23% vs SPY +0.42% |
| 2024Q4ended 2024-12-31 | 2025-03-04 16:30 | - | - | -0.136 | 10.44 | - | EPS - · sales - | vs 2023Q4, year-ago quarter · EPS - · sales +11.6% | - | Open -4.96% vs SPY -0.03%. Close +11.90% vs SPY +1.07% |
| 2024Q3ended 2024-09-30 | 2024-11-07 16:30 | - | - | -0.110 | 9.09 | - | EPS - · sales - | vs 2023Q3, year-ago quarter · EPS - · sales -9.9% | - | Open -3.33% vs SPY +0.09%. Close -0.83% vs SPY +0.43% |
| 2024Q2ended 2024-06-30 | 2024-08-06 16:30 | 0.010 | - | -0.077 | 9.85 | - | EPS - · sales - | vs 2023Q2, year-ago quarter · EPS -93.8% · sales -9.6% | - | Open 0.00% vs SPY +1.21%. Close -1.33% vs SPY -0.67% |
| 2024Q1ended 2024-03-31 | 2024-05-07 16:30 | -0.050 | - | -0.138 | 8.50 | - | EPS - · sales - | vs 2023Q1, year-ago quarter · EPS -145.5% · sales -7.9% | - | Open +9.59% vs SPY -0.36%. Close +5.70% vs SPY +0.01% |
| 2023Q4ended 2023-12-31 | 2024-03-05 16:30 | - | - | -0.444 | 9.35 | - | EPS - · sales - | vs 2022Q4, year-ago quarter · EPS - · sales +2.5% | - | Open -0.50% vs SPY +0.66%. Close -3.00% vs SPY +0.51% |
| 2023Q3ended 2023-09-30 | 2023-11-07 16:30 | 0.020 | - | -0.074 | 10.09 | - | EPS - · sales - | vs 2022Q3, year-ago quarter · EPS -166.7% · sales -11.6% | - | Open 0.00% vs SPY +0.14%. Close -11.71% vs SPY +0.07% |
| 2023Q2ended 2023-06-30 | 2023-08-08 16:30 | 0.160 | - | 0.060 | 10.89 | - | EPS - · sales - | vs 2022Q2, year-ago quarter · EPS -277.8% · sales +5.7% | - | Open +4.90% vs SPY +0.06%. Close +15.38% vs SPY -0.67% |
| 2023Q1ended 2023-03-31 | 2023-05-09 16:30 | 0.110 | - | 0.013 | 9.22 | - | EPS - · sales - | vs 2022Q1, year-ago quarter · EPS -222.2% · sales -17.5% | - | - |
| 2022Q4ended 2022-12-31 | 2023-03-07 16:30 | - | - | -0.170 | 9.12 | - | EPS - · sales - | vs 2021Q4, year-ago quarter · EPS - · sales +9.7% | - | - |
| 2022Q3ended 2022-09-30 | 2022-11-08 16:30 | -0.030 | - | -0.028 | 11.41 | - | EPS - · sales - | vs 2021Q3, year-ago quarter · EPS -57.1% · sales +41.4% | - | - |
| 2022Q2ended 2022-06-30 | 2022-08-10 | -0.090 | - | -0.091 | 10.30 | - | EPS - · sales - | vs 2021Q2, year-ago quarter · EPS -212.5% · sales +13.7% | - | - |
Annual earnings
2021FY EPS -0.240, from -0.220 a year earlier. Sales 35.99, from 37.44 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2021FY | -0.240 | - | -0.240 | 35.99 | - | - |
| 2020FY | -0.220 | -0.220 | -0.220 | 37.44 | 36.96 | - |
| 2019FY | -0.230 | - | -0.230 | 47.53 | - | - |
| 2018FY | -0.450 | -0.550 | -0.446 | 40.74 | 38.23 | - |
| 2017FY | -0.500 | - | -0.500 | 41.15 | - | - |
| 2013FY | -0.110 | - | -0.110 | 32.03 | - | - |
| 2012FY | 0.300 | 0.336 | 0.300 | 48.85 | 48.99 | 22.10 |
| 2011FY | 0.280 | 0.276 | 0.280 | 51.14 | 51.10 | 23.68 |
| 2010FY | 0.120 | 0.114 | 0.120 | 45.88 | 44.51 | 55.25 |
Quarterly results
2026Q3 revenue 2.16, from 8.29 a year earlier. Operating margin -89.8%, from -23.6% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type.
No estimate revisions.
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.5 | -0.446 | -0.23 | -0.22 | -0.235 | -0.383 | -0.439 | -0.461 | -0.191 | -0.7897 | - |
| Sales USD millions | 41 | 41 | 34 | 37 | 36 | 42 | 40 | 38 | 45 | 25 | - |
| Shares million shares | 16 | 15 | 15 | 15 | 15 | 14 | 14 | 14 | 15 | - | 15 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.11 | -0.136 | 0.082 | -0.05 | -0.13 | -0.094 | -0.22 | -0.285 | -0.19 |
| Sales USD millions | 9 | 10 | 12 | 11 | 8 | 14 | 9 | 0 | 2 |
| Shares million shares | 14 | 14 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 25.13 | 44.52+17.6% | 37.87-4.2% | 39.55-5.9% | 42.01+16.7% | 35.99-3.9% | 37.44+8.9% | 34.39-15.6% | 40.74 |
| Cost of Goods Sold Incl. D&A | 7.83 | 10.81-5.9% | 11.49+4.5% | 11.00-23.9% | 14.45+7.7% | 13.42+0.1% | 13.40+13.3% | 11.83+14.2% | 10.36 |
| Gross Profit | 20.47 | 33.71+27.8% | 26.38-7.6% | 28.55+3.6% | 27.56+22.1% | 22.57-6.1% | 24.04+6.6% | 22.56-25.7% | 30.38 |
| Selling, General and Administrative Excl. Other | 26.54 | 36.39+8.7% | 33.48-4.4% | 35.03+5.3% | 33.27+6.0% | 31.39-0.6% | 31.58-3.3% | 32.66-13.4% | 37.73 |
| Research and Development | 4.62 | 5.57+15.6% | 4.82-17.3% | 5.83-12.9% | 6.69+17.8% | 5.68-1.6% | 5.77-16.0% | 6.87-6.1% | 7.32 |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -9.23 | -2.69 | -7.10 | -6.48 | -5.70 | -8.83 | -7.54 | -10.09 | -7.35 |
| Interest Expense | 0.20 | 0.50-18.0% | 0.61-9.0% | 0.67+13.6% | 0.59+490.0% | 0.10-61.5% | 0.26+4.0% | 0.25+25.0% | 0.20 |
| Unusual Expense | - | 0.11 | -0.91-140.4% | 2.25 | 0.00 | -1.15 | -1.16 | -0.80-2100.0% | 0.04 |
| Net Income Before Taxes | -8.76 | -2.81 | -6.47 | -6.28 | -5.58 | -5.56 | -6.57 | -9.29 | -7.02 |
| Income Taxes | 0.03 | 0.04 | -0.02-140.0% | 0.05-28.6% | 0.07+133.3% | 0.03-50.0% | 0.06 | -0.08-500.0% | 0.02 |
| Consolidated Net Income | -8.94 | -2.86 | -6.44 | -6.33 | -5.65 | -5.60 | -6.63 | -9.21 | -7.04 |
| Net Income From Continuing Operations | -8.93 | -2.84 | -6.48 | -6.28 | -5.57 | -5.50 | -6.55 | -9.20 | -6.96 |
| Net Income | -11.83 | -2.84 | -6.48 | -6.28 | -5.57 | -3.51 | -3.34 | -3.54 | -6.96 |
| EPS (Recurring) per share | -0.79 | -0.19 | -0.51 | -0.33 | -0.38 | -0.29 | -0.27 | -0.27 | -0.44 |
| EPS (Basic, Before Extraordinaries) per share | -0.79 | -0.19 | -0.46 | -0.44 | -0.38 | -0.24 | -0.22 | -0.23 | -0.45 |
| EPS (Diluted) per share | -0.79 | -0.19 | -0.46 | -0.44 | -0.38 | -0.24 | -0.22 | -0.23 | -0.45 |
| EBITDA | -7.08 | 2.60 | -1.06 | -0.71 | -0.38 | -4.22 | -2.79 | -5.69 | -4.37 |
| Non-Operating Income (Expense) | 1.05 | 0.48+45.5% | 0.33-89.4% | 3.12+339.4% | 0.71-67.9% | 2.21+2662.5% | 0.08-66.7% | 0.24-57.1% | 0.56 |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.29 | 0.32+33.3% | 0.24-17.2% | 0.29-17.1% | 0.35-35.2% | 0.54-28.9% | 0.76-29.6% | 1.08+10.2% | 0.98 |
| Price To Sales Ratio ratio | 4.67 | 1.33 | 0.88 | 0.65 | 0.78 | 1.93 | 1.19 | 2.31 | 2.31 |
| Gross Margin % | 81.43 | 75.71 | 69.66 | 72.18 | 65.61 | 62.71 | 64.21 | 65.61 | 74.57 |
| Operating Margin % | -36.72 | -6.03 | -18.75 | -16.39 | -13.58 | -24.52 | -20.14 | -29.35 | -18.04 |
| Net Margin % | -47.05 | -6.37 | -17.11 | -15.88 | -13.26 | -9.75 | -8.92 | -10.29 | -17.09 |
| Shares Outstanding million shares | 14.99 | 14.96+7.2% | 13.95-1.2% | 14.12-1.7% | 14.37-2.5% | 14.74-1.7% | 14.99-1.8% | 15.26-1.4% | 15.48 |
| Market Capitalization | 99.34 | 99.34+284.9% | 25.81+24.6% | 20.71-17.9% | 25.24-52.8% | 53.43+55.5% | 34.35-43.4% | 60.64-16.5% | 72.61 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2.16-73.9% | 0.17-98.4% | 9.13-22.0% | 13.68+31.0% | 8.29-8.8% | 10.84+10.1% | 11.71+37.8% | 10.44+11.7% |
| Cost of Goods Sold Incl. D&A | 1.33-34.5% | 0.00-100.0% | 3.21+30.5% | 3.28-5.5% | 2.03-16.8% | 3.05+7.0% | 2.46-9.9% | 3.47+25.7% |
| Gross Profit | 0.82-86.9% | 0.17-97.8% | 5.92-36.1% | 10.40+49.4% | 6.27-5.7% | 7.79+11.3% | 9.26+60.5% | 6.96+5.6% |
| Selling, General and Administrative Excl. Other | 2.76-66.4% | 3.10-63.5% | 8.94+12.9% | 11.73+37.4% | 8.22-6.9% | 8.50+3.2% | 7.92+0.6% | 8.54-1.6% |
| Research and Development | 0.84-32.8% | 0.77-47.6% | 1.46+12.3% | 1.55+20.2% | 1.25-4.6% | 1.47+38.7% | 1.30+12.1% | 1.29+2.4% |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.94 | -2.93 | -3.02-325.4% | -1.34 | -1.96 | -0.71 | 1.34 | -1.57 |
| Interest Expense | 0.00-100.0% | 0.00-100.0% | 0.09-43.8% | 0.11-50.0% | 0.11-21.4% | 0.11-15.4% | 0.16+33.3% | 0.22+22.2% |
| Unusual Expense | - | 0.22+450.0% | 0.11+175.0% | 0.03-88.9% | 0.01 | 0.04 | 0.04 | 0.27-93.4% |
| Net Income Before Taxes | -1.12 | -3.10 | -3.14-351.2% | -1.41 | -1.94 | -0.73 | 1.25 | -1.96 |
| Income Taxes | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.02 | 0.010.0% | 0.010.0% | 0.010.0% | -0.06-400.0% |
| Consolidated Net Income | -1.12 | -3.10 | -3.29-363.2% | -1.43 | -1.95 | -0.74 | 1.25 | -1.90 |
| Net Income From Continuing Operations | -1.12 | -3.11 | -3.29-361.1% | -1.41 | -1.94 | -0.74 | 1.26 | -1.90 |
| Net Income | -2.85 | -4.28 | -3.29-361.1% | -1.41 | -1.94 | -0.74 | 1.26 | -1.90 |
| EPS (Recurring) per share | -0.19 | -0.28 | -0.21-362.5% | -0.09 | -0.13 | -0.05 | 0.08 | -0.12 |
| EPS (Basic, Before Extraordinaries) per share | -0.19 | -0.29 | -0.22-375.0% | -0.09 | -0.13 | -0.05 | 0.08 | -0.14 |
| EPS (Diluted) per share | -0.19 | -0.29 | -0.22-375.0% | -0.09 | -0.13 | -0.05 | 0.08 | -0.14 |
| EBITDA | -1.67 | -3.94-745.9% | -1.46-155.1% | -0.01-104.8% | -0.63 | 0.61+221.1% | 2.65 | 0.21 |
| Non-Operating Income (Expense) | 0.82+530.8% | 0.06-53.8% | 0.08-38.5% | 0.08-27.3% | 0.13-58.1% | 0.13+116.7% | 0.13+30.0% | 0.11+37.5% |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.01-83.3% | 0.060.0% | 0.08+33.3% | 0.14+133.3% | 0.060.0% | 0.060.0% | 0.060.0% | 0.06-14.3% |
| Price To Sales Ratio ratio | 4.67 | 3.10 | 1.16 | 1.34 | 1.13 | 1.19 | 1.57 | 0.87 |
| Gross Margin % | 38.17 | 100.00 | 64.84 | 76.00 | 75.56 | 71.90 | 79.02 | 66.72 |
| Operating Margin % | -89.80 | -1,762.64 | -33.10 | -9.77 | -23.58 | -6.54 | 11.41 | -15.09 |
| Net Margin % | -132.07 | -2,569.04 | -36.03 | -10.32 | -23.40 | -6.84 | 10.73 | -18.24 |
| Shares Outstanding million shares | 14.99+0.2% | 14.98+0.1% | 14.98+0.1% | 14.96+7.2% | 14.96+6.8% | 14.96+6.3% | 14.96+5.6% | 13.95-1.2% |
| Market Capitalization | 99.34+174.5% | 75.29+93.7% | 37.69-17.7% | 46.16+78.8% | 36.19+158.7% | 38.87+130.8% | 45.82+148.1% | 25.81+24.6% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 11.44-36.3% | 17.96-2.0% | 18.32-7.3% | 19.76-26.9% | 27.04+9.3% | 24.75-12.3% | 28.21-22.1% | 36.23-27.7% | 50.09 |
| Short Term Receivables | 16.94+44.8% | 11.70+19.9% | 9.76-25.8% | 13.16+91.3% | 6.88-44.4% | 12.38+57.5% | 7.86+0.3% | 7.84-6.7% | 8.40 |
| Inventories | 6.23+55.8% | 4.00-13.2% | 4.61-53.2% | 9.86+17.0% | 8.43-20.8% | 10.64+20.0% | 8.87-26.6% | 12.08+79.2% | 6.74 |
| Other Current Assets | 2.45-12.2% | 2.79-7.9% | 3.03-1.6% | 3.08-7.8% | 3.34+51.8% | 2.20-57.9% | 5.22+76.4% | 2.96-14.7% | 3.47 |
| Total Current Assets | 37.06+1.7% | 36.45+2.1% | 35.71-22.1% | 45.87+0.4% | 45.69-8.6% | 49.97-0.4% | 50.16-15.2% | 59.12-13.9% | 68.68 |
| Net Property, Plant & Equipment | 8.61+33.5% | 6.45-8.4% | 7.04+28.0% | 5.50+274.1% | 1.47-43.5% | 2.60-29.9% | 3.71+381.8% | 0.77+45.3% | 0.53 |
| Total Investments and Advances | 3.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 14.94-20.9% | 18.89-19.7% | 23.52-25.3% | 31.50+26.8% | 24.84-14.3% | 29.00-8.8% | 31.80-7.7% | 34.44+60.6% | 21.44 |
| Deferred Tax Assets | - | - | - | - | - | 0.66-50.7% | 1.34-35.0% | 2.06-4.2% | 2.15 |
| Other Assets | 12.23-11.3% | 13.79-11.0% | 15.50+54.2% | 10.05-19.4% | 12.47-16.3% | 14.89-21.0% | 18.85+3.1% | 18.28+634.1% | 2.49 |
| Total Assets | 76.82+1.6% | 75.58-7.6% | 81.78-12.0% | 92.93+10.0% | 84.46-13.0% | 97.13-8.2% | 105.86-7.7% | 114.67+20.3% | 95.30 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.47-91.4% | 5.46+1460.0% | 0.35+105.9% | 0.17-82.5% | 0.97-4.9% | 1.02+10.9% | 0.92 | 0.00 | 0.00 |
| Accounts Payable | 18.57+33.5% | 13.91-0.9% | 14.04+29.8% | 10.82+12.2% | 9.64-28.1% | 13.40+34.1% | 9.99-9.9% | 11.09+23.5% | 8.98 |
| Other Current Liabilities | 17.71+44.6% | 12.25-9.9% | 13.60-22.7% | 17.59+102.9% | 8.67-22.9% | 11.25-15.0% | 13.24-20.8% | 16.71+91.8% | 8.71 |
| Total Current Liabilities | 36.74+16.2% | 31.62+13.0% | 27.98-2.1% | 28.58+48.2% | 19.28-24.9% | 25.67+6.3% | 24.15-13.1% | 27.80+57.2% | 17.69 |
| Long Term Debt | 9.71-35.8% | 15.12-16.4% | 18.08-13.0% | 20.79+37.8% | 15.09-6.0% | 16.06-22.0% | 20.58+2.9% | 20.00+104.1% | 9.80 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | - | - | 0.66-49.6% | 1.31-33.5% | 1.97-4.8% | 2.07 |
| Other Liabilities | 5.82-7.6% | 6.30-2.3% | 6.45-15.0% | 7.59+1.3% | 7.49-4.7% | 7.86-10.1% | 8.74-6.2% | 9.32+412.1% | 1.82 |
| Total Liabilities | 52.28-1.4% | 53.04+1.0% | 52.52-7.8% | 56.95+36.0% | 41.86-16.7% | 50.25-8.3% | 54.78-7.3% | 59.10+88.3% | 31.38 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 24.88+8.9% | 22.85-22.8% | 29.60-18.4% | 36.27-15.3% | 42.81-8.9% | 46.99-8.1% | 51.12-8.5% | 55.84-12.9% | 64.12 |
| Total Shareholders Equity | 24.88+8.9% | 22.85-22.8% | 29.60-18.4% | 36.27-15.3% | 42.81-8.9% | 46.99-8.1% | 51.12-8.5% | 55.84-12.9% | 64.12 |
| Accumulated Minority Interest | -0.34 | -0.31 | -0.34 | -0.29 | -0.21 | -0.12 | -0.04 | -0.27 | -0.20 |
| Total Equity | 24.54+8.8% | 22.55-22.9% | 29.26-18.7% | 35.97-15.6% | 42.60-9.1% | 46.87-8.3% | 51.09-8.1% | 55.57-13.1% | 63.92 |
| Total Liabilities & Stockholders Equity | 76.82+1.6% | 75.58-7.6% | 81.78-12.0% | 92.93+10.0% | 84.46-13.0% | 97.13-8.2% | 105.86-7.7% | 114.67+20.3% | 95.30 |
| Book Value Per Share per share | 1.66+1.2% | 1.64-21.9% | 2.10-16.7% | 2.52-13.1% | 2.90-7.6% | 3.14-6.3% | 3.35-7.2% | 3.61-11.5% | 4.08 |
| Tangible Book Value Per Share per share | 0.66+135.7% | 0.28-34.9% | 0.43+30.3% | 0.33-73.0% | 1.22+1.7% | 1.20-5.5% | 1.27-8.0% | 1.38-49.1% | 2.71 |
| Full-Time Employees people | 93+2.2% | 910.0% | 91+7.1% | 85+2.4% | 83-7.8% | 90-4.3% | 94+17.5% | 80-4.8% | 84 |
| Price to Book Ratio ratio | 1.37 | 1.04 | 0.55 | 0.65 | 1.25 | 0.73 | 1.19 | 1.30 | 1.38 |
| Return on Assets % | -3.72 | -8.24 | -7.19 | -6.28 | -6.06 | -6.45 | -8.35 | -6.63 | -8.31 |
| Return on Equity % | -11.88 | -24.71 | -19.07 | -14.09 | -12.25 | -13.34 | -17.21 | -11.61 | -11.62 |
| Return on Invested Capital % | -8.20 | -17.07 | -13.17 | -9.76 | -6.06 | -5.30 | -4.93 | -9.18 | -10.79 |
| Quick Ratio ratio | 0.84 | 1.03 | 1.11 | 1.26 | 1.93 | 1.53 | 1.71 | 1.69 | 3.50 |
| Current Ratio ratio | 1.01 | 1.15 | 1.28 | 1.60 | 2.37 | 1.95 | 2.08 | 2.13 | 3.88 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | 68.79 | -2.86 | -6.44 | -6.33 | -5.65 | -3.60 | -3.42 | -3.55 | -7.04 |
| Depreciation | 2.15 | 5.29-12.4% | 6.04+4.7% | 5.77+8.3% | 5.33+15.6% | 4.61-2.9% | 4.75+8.0% | 4.40+47.7% | 2.98 |
| Other Funds (Non Cash) | -80.18 | 0.35 | -1.50-174.3% | 2.02 | -1.67 | -2.84-646.2% | 0.52+4.0% | 0.50-58.7% | 1.21 |
| Funds from Operations | -9.25 | 2.77 | -1.91-230.8% | 1.46 | -1.99 | -1.84-198.4% | 1.87+31.7% | 1.42 | -2.76 |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 8.31 | 2.16+67.4% | 1.29-72.1% | 4.63-55.7% | 10.44+27.6% | 8.18+131.7% | 3.53+123.4% | 1.58-73.1% | 5.87 |
| Cash from Operating Activities | -0.94 | 4.93 | -0.61-110.0% | 6.09-27.9% | 8.45+33.3% | 6.34+17.2% | 5.41+80.3% | 3.00-3.5% | 3.11 |
| Capital Expenditures | -0.10 | -0.18 | -0.18 | -0.45 | -2.07 | -0.35 | -2.11 | -1.02 | -4.28 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | -13.50 | 0.00 | 0.00 | -5.00 | -20.00 |
| Sale of Fixed Assets and Businesses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | -4.82 | -4.48 | 0.00 | 0.00 | 0.00 | -0.20 | 0.00-100.0% | 8.32 | -3.45 |
| Purchase of Investments | -4.82 | -4.48 | 0.00 | 0.00 | 0.00 | -0.20 | 0.00 | -11.75 | -20.11 |
| Sale Or Maturity of Investments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 20.06+20.4% | 16.66 |
| Other Uses | 99.94 | -0.05 | 0.00 | 0.00 | 0.00 | -0.03 | -0.10 | 0.00 | 0.00 |
| Other Sources | - | 0.00-100.0% | 0.24-31.4% | 0.35-81.6% | 1.90+2011.1% | 0.09-80.4% | 0.46 | 0.00 | - |
| Cash from Investing Activities | 95.02 | -4.71-7950.0% | 0.06 | -0.11 | -13.67 | -0.50 | -1.76-176.5% | 2.30 | -27.72 |
| Cash Dividends Paid | -22.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 4.97 | 5.00 | -0.58 | -0.74 | -1.05 | -1.39 | -1.99 | -3.49 | -3.06 |
| Repurchase of Common Pref Stock | -0.32 | -0.26 | -0.58 | -0.74 | -1.05 | -1.39 | -1.85 | -3.49 | -2.88 |
| Sale of Common Pref Stock | 5.29 | 5.27 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | 0.00 | -0.18 |
| Proceedsfrom Stock Options | 5.29 | 5.27 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | 0.00 | -0.38 |
| Issuance or Reduction of Debt, Net | -5.24 | -10.04-503.2% | 2.49 | -3.42-385.0% | 1.20 | 0.00 | -3.50 | -1.50-114.7% | 10.20 |
| Change in Long Term Debt | -5.24 | -10.04-503.2% | 2.49 | -3.42-385.0% | 1.20 | 0.00 | -3.50 | -1.50-114.7% | 10.20 |
| Issuance of Long Term Debt | - | 0.00-100.0% | 38.49+22.3% | 31.48-40.5% | 52.90-10.3% | 59.000.0% | 59.00-22.4% | 76.00+35.7% | 56.00 |
| Reduction of Long Term Debt | -5.24 | -10.04 | -36.00 | -34.89 | -51.70 | -59.00 | -62.50 | -77.50 | -45.80 |
| Net Financing Active Other Cash Flow | -5.95 | -1.71 | -1.72 | -3.27 | -2.21 | -2.17 | -1.62 | -0.03 | 0.00 |
| Other Financing Activities Uses | -0.68 | -1.71 | -1.72 | -3.27 | -2.21 | -2.17 | -1.62 | -1.03 | 0.00 |
| Cash from Financing Activities | -28.70 | -6.75-3475.0% | 0.20 | -7.42 | -2.06 | -3.55 | -7.11 | -5.03-170.4% | 7.14 |
| Net Change in Cash | 65.38 | -6.52 | -0.36 | -1.44 | -7.28-417.9% | 2.29 | -3.46-1381.5% | 0.27 | -17.47 |
| Free Cash Flow | -0.99 | 4.83 | -0.68-111.7% | 5.81-30.4% | 8.35+33.8% | 6.24+18.6% | 5.26+90.6% | 2.76+3.8% | 2.66 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow ratio | - | 12.23 | - | 4.41 | 3.92 | 11.16 | 8.50 | 28.75 | 35.43 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.02-71.4% | 0.07-12.5% | 0.08 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 80.58+430.1% | 3.86-76.0% | 11.01-27.1% | 11.44-36.3% | 15.20-12.9% | 16.09-7.2% | 15.11-18.5% | 17.96-2.0% |
| Short Term Receivables | 23.12+121.7% | 13.42+30.0% | 14.26+35.9% | 16.94+44.8% | 10.43-7.8% | 10.32-11.2% | 10.49-1.5% | 11.70+19.9% |
| Inventories | 0.03-99.0% | 0.03-99.1% | 5.45+32.9% | 6.23+55.8% | 2.93-35.0% | 3.22-25.1% | 4.10-5.3% | 4.00-13.2% |
| Other Current Assets | 0.83-39.9% | 16.33+933.5% | 2.07-5.0% | 2.45-12.2% | 1.38-29.2% | 1.58-31.9% | 2.18-18.7% | 2.79-7.9% |
| Total Current Assets | 104.56+249.2% | 33.64+7.8% | 32.79+2.9% | 37.06+1.7% | 29.94-15.0% | 31.21-12.3% | 31.88-12.0% | 36.45+2.1% |
| Net Property, Plant & Equipment | 7.42-5.6% | 7.53+1.5% | 7.86+5.1% | 8.61+33.5% | 7.86+20.6% | 7.42+10.7% | 7.48+8.6% | 6.45-8.4% |
| Total Investments and Advances | - | 0.00 | 3.84 | 3.99 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.04-99.7% | 0.04-99.8% | 13.71-23.4% | 14.94-20.9% | 15.92-21.7% | 16.90-20.9% | 17.90-20.2% | 18.89-19.7% |
| Other Assets | 1.76-85.5% | 21.66+75.0% | 12.80+0.9% | 12.23-11.3% | 12.17-17.0% | 12.38-16.7% | 12.68-20.7% | 13.79-11.0% |
| Total Assets | 113.78+72.7% | 62.88-7.4% | 71.00+1.5% | 76.82+1.6% | 65.90-14.1% | 67.91-13.5% | 69.94-14.2% | 75.58-7.6% |
| Short Term Debt Incl. Current Port. of LT Debt | 0.52+30.0% | 0.50+28.2% | 0.49+32.4% | 0.47-91.4% | 0.40-93.7% | 0.39+2.6% | 0.37+2.8% | 5.46+1460.0% |
| Accounts Payable | 16.50+19.3% | 19.55+45.4% | 16.54+18.7% | 18.57+33.5% | 13.83+14.7% | 13.45+7.5% | 13.93+6.5% | 13.91-0.9% |
| Other Current Liabilities | 17.31+71.7% | 15.14+49.3% | 17.47+55.7% | 17.71+44.6% | 10.08-20.3% | 10.14-14.6% | 11.22-13.6% | 12.25-9.9% |
| Total Current Liabilities | 34.33+41.2% | 35.19+46.8% | 34.49+35.1% | 36.74+16.2% | 24.31-21.8% | 23.97-3.2% | 25.52-3.4% | 31.62+13.0% |
| Long Term Debt | 4.07-58.6% | 4.21-57.7% | 9.58-4.9% | 9.71-35.8% | 9.84-34.8% | 9.95-53.0% | 10.07-52.7% | 15.12-16.4% |
| Provision for Risks Charges | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 3.20-46.2% | 6.37+1.1% | 5.62-6.5% | 5.82-7.6% | 5.95-2.3% | 6.30-3.7% | 6.01-9.1% | 6.30-2.3% |
| Total Liabilities | 41.60+3.7% | 45.77+13.8% | 49.69+19.4% | 52.28-1.4% | 40.10-23.3% | 40.23-23.4% | 41.60-23.4% | 53.04+1.0% |
| Non-Equity Reserves | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 72.51+177.6% | 17.44-37.7% | 21.64-24.5% | 24.88+8.9% | 26.12+5.4% | 27.99+6.2% | 28.66+4.3% | 22.85-22.8% |
| Total Shareholders Equity | 72.51+177.6% | 17.44-37.7% | 21.64-24.5% | 24.88+8.9% | 26.12+5.4% | 27.99+6.2% | 28.66+4.3% | 22.85-22.8% |
| Accumulated Minority Interest | -0.33 | -0.33 | -0.33 | -0.34 | -0.32 | -0.31 | -0.32 | -0.31 |
| Total Equity | 72.18+179.8% | 17.11-38.2% | 21.30-24.8% | 24.54+8.8% | 25.80+5.4% | 27.68+6.3% | 28.34+4.2% | 22.55-22.9% |
| Total Liabilities & Stockholders Equity | 113.78+72.7% | 62.88-7.4% | 71.00+1.5% | 76.82+1.6% | 65.90-14.1% | 67.91-13.5% | 69.94-14.2% | 75.58-7.6% |
| Book Value Per Share per share | 4.84+176.6% | 1.16-38.0% | 1.44-25.0% | 1.66+1.2% | 1.75-1.1% | 1.870.0% | 1.92-1.0% | 1.64-21.9% |
| Tangible Book Value Per Share per share | 4.83+610.3% | 1.16+56.8% | 0.53-26.4% | 0.66+135.7% | 0.68+112.5% | 0.74+111.4% | 0.72+100.0% | 0.28-34.9% |
| Full-Time Employees people | - | - | - | 93+2.2% | - | - | - | 910.0% |
| Price to Book Ratio ratio | 1.37 | 3.48 | 1.51 | 1.77 | 1.29 | 1.36 | 2.00 | 1.04 |
| Return on Assets % | -9.94 | -14.91 | -10.48 | -3.72 | -4.67 | -4.00 | -4.33 | -8.24 |
| Return on Equity % | -18.11 | -42.92 | -29.36 | -11.88 | -13.08 | -10.79 | -11.67 | -24.71 |
| Return on Invested Capital % | -3.72 | -19.75 | -10.54 | -4.08 | -5.40 | -1.95 | 3.25 | -5.01 |
| Quick Ratio ratio | 3.04 | 0.96 | 0.79 | 0.84 | 1.11 | 1.17 | 1.09 | 1.03 |
| Current Ratio ratio | 3.05 | 0.96 | 0.95 | 1.01 | 1.23 | 1.30 | 1.25 | 1.15 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | 77.78 | -4.27 | -3.29-363.2% | -1.43 | -1.95 | -0.74 | 1.25 | -1.90 |
| Depreciation | 0.27-79.5% | -1.01-176.5% | 1.56+18.2% | 1.33-25.3% | 1.32-5.7% | 1.32-7.0% | 1.32-8.3% | 1.78-14.0% |
| Other Funds (Non Cash) | -84.39 | 3.96 | 0.12-42.9% | 0.13 | 0.00 | 0.00 | 0.21 | -0.40-113.0% |
| Funds from Operations | -6.34 | -1.33-325.4% | -1.61-158.1% | 0.03 | -0.62 | 0.59+181.0% | 2.77 | -0.52 |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 4.84+497.5% | 1.50+476.9% | 2.00+77.0% | -0.03-101.2% | 0.81-39.1% | 0.26 | 1.13 | 2.43+11.0% |
| Cash from Operating Activities | -1.50-889.5% | 0.17-79.8% | 0.39-90.0% | 0.00-100.0% | 0.19-60.4% | 0.84 | 3.90 | 1.90+82.7% |
| Capital Expenditures | -0.01 | -0.03 | -0.02 | -0.04 | -0.03 | -0.04 | -0.07 | -0.03 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -0.04 | -1.75-630.3% | 0.00 | -3.03 | -0.61 | 0.33 | -1.16 | 0.00 |
| Purchase of Investments | -0.04 | -1.75-630.3% | 0.00 | -3.03 | -0.61 | 0.33 | -1.16 | 0.00 |
| Sale Or Maturity of Investments | - | 0.00 | 0.00 | - | - | - | - | 0.00 |
| Other Uses | 100.13 | -0.15 | -0.04 | 0.00 | -0.05 | 0.00 | 0.00 | 0.00 |
| Other Sources | - | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 | 0.00 | 0.00-100.0% |
| Cash from Investing Activities | 100.08 | -1.93-765.5% | -0.06 | -3.07 | -0.69-463.2% | 0.29 | -1.23 | -0.03-111.5% |
| Cash Dividends Paid | -22.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -0.24 | 0.00 | -0.06 | 5.27 | -0.01 | -0.01 | -0.25 | -0.10 |
| Repurchase of Common Pref Stock | -0.26 | 0.00 | -0.06 | 0.00 | -0.01 | -0.01 | -0.25 | -0.10 |
| Sale of Common Pref Stock | 0.02 | 0.00 | 0.00 | 5.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 0.02 | 0.00 | 0.00 | 5.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | -5.24 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | -10.04-404.2% | -0.82 |
| Change in Long Term Debt | 0.00 | -5.24 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | -10.04-404.2% | -0.82 |
| Issuance of Long Term Debt | - | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 5.50-28.6% |
| Reduction of Long Term Debt | 0.00 | -5.24 | 0.00 | 0.00 | 0.00 | 0.00 | -10.04 | -6.32 |
| Net Financing Active Other Cash Flow | 0.85 | -0.15 | -0.70-114.7% | -5.95 | -0.38 | -0.14 | 4.76 | -0.46 |
| Other Financing Activities Uses | 0.85 | -0.15 | -0.70 | -0.68 | -0.38 | -0.14 | -0.51 | -0.46 |
| Cash from Financing Activities | -21.87 | -5.39 | -0.76 | -0.68 | -0.39 | -0.15 | -5.53-328.5% | -1.38 |
| Net Change in Cash | 76.72 | -7.14-828.6% | -0.44 | -3.75-850.0% | -0.89-784.6% | 0.98 | -2.86-1343.5% | 0.50 |
| Free Cash Flow | -1.51-1043.8% | 0.13-84.1% | 0.39-89.9% | 0.00-100.0% | 0.16-65.2% | 0.82 | 3.85 | 1.90+91.9% |
| Price to Free Cash Flow ratio | - | 141.95 | 35.47 | 12.31 | 6.93 | 7.13 | 12.06 | - |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Product - Acetadote | 0.19 | 0.51 | +174.4% | 1.1% |
| Product - Caldolor | 4.96 | 4.66 | -6.0% | 10.5% |
| Product - Kristalose | 15.32 | 10.54 | -31.2% | 23.7% |
| Product - Omeclamox-Pak | 0.00 | -0.01 | +239.4% | 0.0% |
| Product - Other | 1.33 | 4.13 | +210.1% | 9.3% |
| Product - RediTrex | 0.09 | 0.01 | -87.4% | 0.0% |
| Product - Sancuso | 9.01 | 11.91 | +32.2% | 26.7% |
| Product - Talicia | - | 3.31 | - | 7.4% |
| Product - Vaprisol | -0.17 | -0.02 | -89.5% | 0.0% |
| Product - Vibativ | 7.16 | 9.48 | +32.5% | 21.3% |
| Total | 37.87 | 44.52 | +17.6% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 37.87 | 44.52 | +17.6% | 100.0% |
| Total | 37.87 | 44.52 | +17.6% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 3.43% | 0.3M | 8.8M | 85.37K |
| 2026-10-15 | 3.84% | 0.3M | 8.8M | 87.33K |
| 2026-09-30 | 3.99% | 0.3M | 8.8M | 101.24K |
| 2026-09-15 | 2.89% | 0.3M | 8.8M | 104.52K |
| 2026-08-31 | 3.14% | 0.3M | 8.8M | 109.98K |
| 2026-08-14 | 3.73% | 0.3M | 8.8M | 133.00K |
| 2026-07-31 | 4.42% | 0.4M | 8.8M | 148.40K |
| 2026-07-15 | 4.26% | 0.4M | 8.8M | 991.42K |
| 2026-06-30 | 2.77% | 0.2M | 8.8M | 968.21K |
| 2026-06-15 | 3.87% | 0.3M | 8.8M | 955.95K |
| 2026-05-29 | 4.06% | 0.4M | 8.7M | 984.83K |
| 2026-05-15 | 5.20% | 0.5M | 8.7M | 979.53K |
| 2026-04-30 | 6.00% | 0.5M | 8.7M | 999.81K |
| 2026-04-15 | 1.29% | 0.1M | 8.7M | 129.47K |
| 2026-03-31 | 1.27% | 0.1M | 8.6M | 162.03K |
| 2026-03-13 | 1.65% | 0.1M | 8.6M | 214.62K |
| 2026-02-27 | 2.09% | 0.2M | 8.6M | 208.77K |
| 2026-02-13 | 2.24% | 0.2M | 8.6M | 198.04K |
| 2026-01-30 | 0.87% | 0.1M | 8.7M | 175.15K |
| 2026-01-15 | 1.16% | 0.1M | 8.7M | 148.64K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 2.95 | 5.50 | 2.10 | 1431.6% | 6.00 | 0.00 | 0.974 | -0.016 | 0.001 |
| call | 5.00 | 0.45 | 2.90 | 0.83 | 604.8% | 314 | 0.00 | 0.926 | -0.013 | 0.001 |
| call | 7.50 | 0.15 | 0.45 | 0.40 | 197.1% | 1,336 | 663 | 0.390 | -0.047 | 0.004 |
| call | 10.00 | 0.00 | 1.85 | 0.05 | 337.2% | 101 | 0.00 | 0.280 | -0.071 | 0.003 |
| call | 12.50 | 0.00 | 1.85 | 0.16 | 427.3% | 50.00 | 0.00 | 0.242 | -0.083 | 0.003 |
| call | 15.00 | 0.00 | 1.85 | 0.00 | 494.2% | 0.00 | 0.00 | 0.222 | -0.091 | 0.003 |
| put | 2.50 | 0.00 | 1.25 | 0.05 | 407.1% | 26.00 | 0.00 | -0.026 | -0.015 | 0.001 |
| put | 5.00 | 0.00 | 0.05 | 0.03 | 165.9% | 31.00 | 1.00 | -0.060 | -0.013 | 0.001 |
| put | 7.50 | 0.00 | 2.05 | 0.57 | 388.7% | 79.00 | 0.00 | -0.610 | -0.046 | 0.004 |
| put | 10.00 | 2.15 | 4.60 | 0.00 | 552.8% | 0.00 | 0.00 | -0.720 | -0.069 | 0.003 |
| put | 12.50 | 4.50 | 7.10 | 0.00 | 651.7% | 0.00 | 0.00 | -0.758 | -0.081 | 0.003 |
| put | 15.00 | 7.00 | 9.60 | 0.00 | 725.3% | 0.00 | 0.00 | -0.778 | -0.090 | 0.003 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | 8-K | Current report | 2026-11-10 | SEC |
| 2026-10-26 | 8-K | Current report | 2026-10-26 | SEC |
| 2026-10-23 | 8-K | Current report | 2026-10-23 | SEC |
| 2026-09-11 | 8-K/A | 2026-04-21 | SEC | |
| 2026-08-28 | 8-K | Current report | 2026-08-28 | SEC |
| 2026-08-07 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-04 | 8-K | Current report | 2026-08-04 | SEC |
| 2026-07-13 | 8-K | Current report | 2026-07-13 | SEC |
| 2026-07-01 | 8-K | Current report | 2026-06-29 | SEC |
| 2026-06-25 | 8-K | Current report | 2026-06-24 | SEC |
| 2026-05-26 | DEFM14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-05-15 | PREM14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-05-15 | SEC |
| 2026-05-08 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-05 | 8-K | Current report | 2026-05-05 | SEC |
| 2026-04-24 | 8-K | Current report | 2026-04-21 | SEC |
| 2026-04-23 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-04-23 | 8-K | Current report | 2026-04-22 | SEC |
| 2026-03-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-16 | SEC |
| 2026-03-12 | ARS | Annual report to security holders. | 2026-03-12 | SEC |
| 2026-03-09 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Diversified Trust Co | 4.67% |
| Ikarian Capital, LLC | 3.36% |
| RENAISSANCE TECHNOLOGIES LLC | 2.85% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.53% |
| DIMENSIONAL FUND ADVISORS LP | 1.23% |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.75% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.73% |
| PERCEPTIVE ADVISORS LLC | 0.65% |
| JANE STREET GROUP, LLC | 0.54% |
| CITADEL ADVISORS LLC | 0.49% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 1.83% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.67% |
| Dimensional U.S. Small Cap ETF | 0.33% |
| U.S. MICRO CAP PORTFOLIO | 0.32% |
| Fidelity Extended Market Index Fund | 0.31% |
| U.S. Targeted Value Portfolio | 0.25% |
| iShares Micro-Cap ETF | 0.19% |
| Ultra-Small Company Market Fund | 0.17% |
| Nationwide Bailard Small Cap Value Fund | 0.16% |
| Fidelity Total Market Index Fund | 0.12% |
OakChart. CPIX. Cached 15 minutes. Terms
Some panels did not load: insider.